IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
Module I Summary
In this session, we summarize the key takeaways from Sessions 1-5 and further elaborate on some of the questions received by attendees throughout Module I. We will also provide an overview of a Reference Guide we have prepared and introduce the content for next year’s sessions, which will focus on specific organs and relevant COUs.
Date & Time
Monday, December 4, 2023 at 1:00 pm ET
Duration
90 minutes
Agenda
Welcome and Introduction
Aaron Fullerton, Genentech
Lessons from Module I Sessions 1-3 (Introduction to CIVM/MPS and Technical Considerations for Experiemental Design)
Jason Ekert, UCB
Rhiannon David, Astrazeneca,
Tom Chan, BMS
James Gosset, Pfizer
Q&A / Discussion
Deidre Dalmas Wilk, GSK
Lessons from Module I Sessions 4-5 (Leveraging MPS Data for In Silico Modeling and CIVM/MPS Qualification Considerations)
Dave Stresser, AbbVie
Aaron Fullerton, Genentech
Q&A / Discussion
Deidre Dalmas Wilk, GSK
Module I Closing Remarks
Nakissa Sadrieh, FDA
Introduction to Module II: Established CIVM/MPS (Organ-Specific Sessions)
Deidre Dalmas Wilk, GSK
Moderators and Presenters
